LVAD DT denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for lvad dt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies LVAD Destination Therapy as Duplicate Therapy

A left ventricular assist device used as destination therapy (LVAD-DT) is a surgically implanted mechanical circulatory support device for patients with advanced heart failure who are not candidates for heart transplantation. Aetna may issue a duplicate-therapy denial when it determines that another active mechanical circulatory support device, surgical intervention, or advanced heart failure treatment is already in place or already authorized, and it views LVAD-DT as redundant. This type of denial requires immediate clinical scrutiny — LVAD-DT is not interchangeable with other therapies, and "duplicate" in this context is almost certainly a coverage-determination error.

## Why This Denial Is Appealable

Duplicate-therapy denials for LVAD-DT are highly appealable because LVAD-DT has a specific, defined patient population and no true therapeutic equivalent for that population. ACA §2719 requires external review access for non-grandfathered plans. ERISA §503 requires full-and-fair review for employer-sponsored plans. File an internal appeal within the deadline on the denial notice. Request external review within approximately four months of exhausting internal remedies. Given the life-sustaining nature of LVAD-DT, request expedited (72-hour) external review on the grounds that delay would seriously jeopardize the patient's health or life.

## The Concrete Appeal Process

1. Identify the alleged duplicate: obtain from Aetna a written explanation of which specific therapy or device it considers duplicative. 2. Document clinical distinction: have the treating cardiologist or heart failure specialist explain in writing why the alleged duplicate is not clinically equivalent. 3. File an urgent internal appeal given the life-sustaining nature of the device. 4. Request expedited external review simultaneously if the internal timeline creates clinical risk.

## Documentation to Gather

• Cardiology team's clinical differentiation letter: a letter from the treating heart failure specialist explaining why LVAD-DT is not duplicative of any other current or authorized therapy, and why it is the medically necessary treatment for this patient.
• Current treatment list: a complete list of all active cardiac treatments and devices, with clinical roles, demonstrating there is no true duplicate.
• Advanced heart failure diagnosis documentation: chart notes confirming the diagnosis, disease stage per the applicable heart failure classification system (reference the guideline organization, not specific scores), and transplant ineligibility status.
• FDA-approved device labeling: the indication for use from the device's FDA-approved labeling, confirming LVAD-DT's defined clinical role.
• Applicable guideline reference: the treating physician may reference the relevant cardiovascular guideline organization (such as the ACC/AHA) to support clinical differentiation.

## Criteria-Mapping Structure

For a duplicate-therapy appeal, the organizing question is: "What specifically does Aetna claim is the duplicate, and how is LVAD-DT clinically distinct from it?" Address that question directly. Attach the FDA labeling, the cardiology letter, the current therapy list, and the applicable guideline reference. Request that Aetna's denial letter identify the exact therapy it considers duplicative — if it cannot, that is itself grounds for reversal.